{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:00:45Z","timestamp":1790262045120,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01589-1","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:14:24Z","timestamp":1787660064000},"page":"1197-1208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin Use and Arterial Calcification in the General Population: A Longitudinal Analysis and a Negative Control Population"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-3591","authenticated-orcid":false,"given":"Mitra","family":"Nekouei Shahraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A","family":"Labrecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Ahmadizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno H","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kavousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"25","key":"1589_CR1","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"5","key":"1589_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pcad.2019.11.005","volume":"62","author":"NJ Stone","year":"2018","unstructured":"Stone NJ, Grundy SM. The 2018 AHA\/ACC\/Multi-Society cholesterol guidelines: looking at past, present and future. Prog Cardiovasc Dis. 2018;62(5):375\u201383.","journal-title":"Prog Cardiovasc Dis"},{"issue":"34","key":"1589_CR3","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00210-016-1252-4","volume":"389","author":"O Bedi","year":"2016","unstructured":"Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:695\u2013712.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1589_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","volume":"99","author":"AS Wierzbicki","year":"2003","unstructured":"Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99(1):95\u2013112.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1589_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/cvr\/cvab032","volume":"118","author":"D Yu","year":"2022","unstructured":"Yu D, Liao JK. Emerging views of statin pleiotropy and cholesterol lowering. Cardiovasc Res. 2022;118(2):413\u201323.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1589_CR7","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2502051","volume":"25","author":"NPE Kadoglou","year":"2024","unstructured":"Kadoglou NPE, Stasinopoulou M, Velidakis N, Khattab E, Christodoulou E, Gkougkoudi E, et al. The complex mechanisms and the potential effects of statins on vascular calcification: a narrative review. Rev Cardiovasc Med. 2024;25(2):51.","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"1589_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1161\/ATVBAHA.119.313832","volume":"40","author":"A Healy","year":"2020","unstructured":"Healy A, Berus JM, Christensen JL, Lee C, Mantsounga C, Dong W, et al. Statins disrupt macrophage Rac1 regulation leading to increased atherosclerotic plaque calcification. Arterioscler Thromb Vasc Biol. 2020;40(3):714\u201332.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1589_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41419-022-04923-5","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Wang Z-W, Fang L-J, Cheng S-Q, Wang X, Liu N-F. Programmed cell death in atherosclerosis and vascular calcification. Cell Death Dis. 2022;13(5):467.","journal-title":"Cell Death Dis"},{"key":"1589_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1215612","volume":"14","author":"JG Neels","year":"2023","unstructured":"Neels JG, Gollentz C, Chinetti G. Macrophage death in atherosclerosis: potential role in calcification. Front Immunol. 2023;14:1215612.","journal-title":"Front Immunol"},{"issue":"1","key":"1589_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jcmg.2020.08.036","volume":"14","author":"H-Y Jin","year":"2021","unstructured":"Jin H-Y, Weir-McCall JR, Leipsic JA, Son J-W, Sellers SL, Shao M, et al. The relationship between coronary calcification and the natural history of coronary artery disease. JACC Cardiovasc Imaging. 2021;14(1):233\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"1589_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2021.06.049","volume":"78","author":"P Lanzer","year":"2021","unstructured":"Lanzer P, Hannan FM, Lanzer JD, Janzen J, Raggi P, Furniss D, et al. Medial arterial calcification: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(11):1145\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1589_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/alz.13496","volume":"20","author":"TC van den Beukel","year":"2024","unstructured":"van den Beukel TC, Wolters FJ, Siebert U, Spiering W, Ikram MA, Vernooij MW, et al. Intracranial arteriosclerosis and the risk of dementia: a population-based cohort study. Alzheimers Dement. 2024;20(2):869\u201379.","journal-title":"Alzheimers Dement"},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11883-023-01151-w","volume":"25","author":"MN Shahraki","year":"2023","unstructured":"Shahraki MN, Jouabadi SM, Bos D, Stricker BH, Ahmadizar F. Statin use and coronary artery calcification: a systematic review and meta-analysis of observational studies and randomized controlled trials. Curr Atheroscler Rep. 2023;25:769\u201384.","journal-title":"Curr Atheroscler Rep"},{"key":"1589_CR15","unstructured":"Gu Q. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012: US Department of Health and Human Services, Centers for Disease Control and\u00a0\u2026; 2014."},{"issue":"7","key":"1589_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289111","volume":"18","author":"KS Ngamdu","year":"2023","unstructured":"Ngamdu KS, Ghosalkar DS, Chung HE, Christensen JL, Lee C, Butler CA, et al. Long-term statin therapy is associated with severe coronary artery calcification. PLoS ONE. 2023;18(7):e0289111.","journal-title":"PLoS ONE"},{"issue":"1","key":"1589_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.5547","volume":"32","author":"EK Acton","year":"2023","unstructured":"Acton EK, Willis AW, Hennessy S. Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf. 2023;32(1):9\u201318.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1589_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291\u2013303.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1589_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen ET, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383\u20138.","journal-title":"Epidemiology"},{"issue":"3","key":"1589_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/EDE.0000000000001724","volume":"35","author":"M Piccininni","year":"2024","unstructured":"Piccininni M, Stensrud MJ. Using negative control populations to assess unmeasured confounding and direct effects. Epidemiology. 2024;35(3):313\u20139.","journal-title":"Epidemiology"},{"issue":"3","key":"1589_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693\u2013705.","journal-title":"Br J Pharmacol"},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","volume":"35","author":"MA Ikram","year":"2020","unstructured":"Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, et al. Objectives, design and main findings until 2020 from the Rotterdam study. Eur J Epidemiol. 2020;35:483\u2013517.","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"1589_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003843","volume":"8","author":"D Bos","year":"2015","unstructured":"Bos D, Leening MJG, Kavousi M, Hofman A, Franco OH, Lugt AV, et al. Comparison of atherosclerotic calcification in major vessel beds on the risk of all-cause and cause-specific mortality: the Rotterdam study. Circ Cardiovasc Imaging. 2015;8(12):e003843.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"1589_CR24","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1161\/STROKEAHA.111.648667","volume":"43","author":"D Bos","year":"2012","unstructured":"Bos D, van der Rijk MJM, Geeraedts TEA, Hofman A, Krestin GP, Witteman JCM, et al. Intracranial carotid artery atherosclerosis: prevalence and risk factors in the general population. Stroke. 2012;43(7):1878\u201384.","journal-title":"Stroke"},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Van Buuren","year":"2011","unstructured":"Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","volume":"372","author":"J K\u00f6nig","year":"2006","unstructured":"K\u00f6nig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432\u201343.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"1589_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clpt.2005.11.003","volume":"79","author":"DA Katz","year":"2006","unstructured":"Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006;79(3):186\u201396.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1589_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/cpt.1489","volume":"106","author":"CH van der Wouden","year":"2019","unstructured":"van der Wouden CH, van Rhenen MH, Jama WOM, Ingelman-Sundberg M, Lauschke VM, Konta L, et al. Development of the PG x-Passport: a panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing. Clin Pharmacol Ther. 2019;106(4):866\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1589_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","volume":"15","author":"Y Kameyama","year":"2005","unstructured":"Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1* 5, SLCO1B1* 15 and SLCO1B1* 15+ C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513\u201322.","journal-title":"Pharmacogenet Genomics"},{"key":"1589_CR30","doi-asserted-by":"crossref","unstructured":"Niemi M. Role of OATP transporters in the disposition of drugs. 2007.","DOI":"10.2217\/14622416.8.7.787"},{"issue":"12","key":"1589_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom. 2006;16(12):873\u20139.","journal-title":"Pharmacogenet Genom"},{"issue":"3","key":"1589_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"S Mwer","year":"1988","unstructured":"Mwer S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1589_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/clpt.2014.125","volume":"96","author":"LB Ramsey","year":"2014","unstructured":"Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1589_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1037\/a0012765","volume":"53","author":"O-M Kwok","year":"2008","unstructured":"Kwok O-M, Underhill AT, Berry JW, Luo W, Elliott TR, Yoon M. Analyzing longitudinal data with multilevel models: an example with individuals living with lower extremity intra-articular fractures. Rehabil Psychol. 2008;53(3):370.","journal-title":"Rehabil Psychol"},{"issue":"4","key":"1589_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezac429","volume":"62","author":"X Wang","year":"2022","unstructured":"Wang X, Andrinopoulou E-R, Veen KM, Bogers AJJC, Takkenberg JJM. Statistical primer: an introduction to the application of linear mixed-effects models in cardiothoracic surgery outcomes research\u2014a case study using homograft pulmonary valve replacement data. Eur J Cardiothorac Surg. 2022;62(4):ezac429.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1589_CR36","first-page":"1","volume":"67","author":"D Bates","year":"2014","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2014;67:1\u201348.","journal-title":"J Stat Softw"},{"issue":"1","key":"1589_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1589_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221\u20138.","journal-title":"Curr Epidemiol Rep"},{"issue":"8","key":"1589_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","volume":"29","author":"SO Almeida","year":"2019","unstructured":"Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med. 2019;29(8):451\u20135.","journal-title":"Trends Cardiovasc Med"},{"issue":"11","key":"1589_CR40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamacardio.2021.3055","volume":"6","author":"AR Van Rosendael","year":"2021","unstructured":"Van Rosendael AR, Van Den Hoogen IJ, Gianni U, Ma X, Tantawy SW, Bax AM, et al. Association of statin treatment with progression of coronary atherosclerotic plaque composition. JAMA Cardiol. 2021;6(11):1257\u201366.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1589_CR41","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1007\/s00330-023-10566-7","volume":"34","author":"JE van der Toorn","year":"2024","unstructured":"van der Toorn JE, Vernooij MW, Ikram MA, Kavousi M, Bos D. Progression of arterial calcifications: what, where, and in whom? Eur Radiol. 2024;34(8):5142\u201352.","journal-title":"Eur Radiol"},{"key":"1589_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.900579","volume":"13","author":"GM Fote","year":"2022","unstructured":"Fote GM, Raefsky S, Mock K, Chaudhari A, Shafie M, Yu W. Intracranial arterial calcifications: potential biomarkers of stroke risk and outcome. Front Neurol. 2022;13:900579.","journal-title":"Front Neurol"},{"issue":"5","key":"1589_CR43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jcmg.2017.03.005","volume":"10","author":"T Nakahara","year":"2017","unstructured":"Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary artery calcification: from mechanism to molecular imaging. JACC Cardiovasc Imaging. 2017;10(5):582\u201393.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1589_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1161\/01.CIR.94.5.1175","volume":"94","author":"L Wexler","year":"1996","unstructured":"Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation. 1996;94(5):1175\u201392.","journal-title":"Circulation"},{"issue":"13","key":"1589_CR45","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365.","journal-title":"JAMA"},{"issue":"3","key":"1589_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2176\/nmc.50.179","volume":"50","author":"T Masuoka","year":"2010","unstructured":"Masuoka T, Hayashi N, Hori E, Kuwayama N, Ohtani O, Endo S. Distribution of internal elastic lamina and external elastic lamina in the internal carotid artery: possible relationship with atherosclerosis. Neurol Med Chir (Tokyo). 2010;50(3):179\u201382.","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"1589_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/17474930251322678","volume":"20","author":"BP Berghout","year":"2025","unstructured":"Berghout BP, Soyupak RF, Ikram MK, Bos D. Variations in intracranial arterial anatomy of the circle of Willis and their association with arteriosclerosis in patients with ischemic cerebrovascular disease. Int J Stroke. 2025;20:843\u201351.","journal-title":"Int J Stroke"},{"issue":"1","key":"1589_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/STROKEAHA.115.011196","volume":"47","author":"A Vos","year":"2016","unstructured":"Vos A, Van Hecke W, Spliet WGM, Goldschmeding R, Isgum I, Kockelkoren R, et al. Predominance of nonatherosclerotic internal elastic lamina calcification in the intracranial internal carotid artery. Stroke. 2016;47(1):221\u20133.","journal-title":"Stroke"},{"key":"1589_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11883-009-0073-z","volume":"12","author":"EA Gill","year":"2010","unstructured":"Gill EA. Does statin therapy affect the progression of atherosclerosis measured by a coronary calcium score? Curr Atheroscler Rep. 2010;12:83\u20137.","journal-title":"Curr Atheroscler Rep"},{"key":"1589_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2020.05.017","volume":"306","author":"H Jinnouchi","year":"2020","unstructured":"Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, Mori M, Kawakami R, et al. Calcium deposition within coronary atherosclerotic lesion: implications for plaque stability. Atherosclerosis. 2020;306:85\u201395.","journal-title":"Atherosclerosis"},{"key":"1589_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcmg.2017.10.012","volume":"11","author":"H Mori","year":"2018","unstructured":"Mori H, Torii S, Kutyna M, Sakamoto A, Finn AV, Virmani R. Coronary artery calcification and its progression: what does it really mean? JACC Cardiovasc Imaging. 2018;11:127\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"1589_CR52","doi-asserted-by":"publisher","DOI":"10.1148\/ryct.2020200281","volume":"2","author":"S Adelhoefer","year":"2020","unstructured":"Adelhoefer S, Uddin SMI, Osei AD, Obisesan OH, Blaha MJ, Dzaye O. Coronary artery calcium scoring: new insights into clinical interpretation\u2014lessons from the CAC Consortium. Radiol Cardiothorac Imaging. 2020;2(6):e200281.","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"5","key":"1589_CR53","first-page":"1175","volume":"13","author":"GR Grandhi","year":"2020","unstructured":"Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, et al. Interplay of coronary artery calcium and risk factors for predicting CVD\/CHD mortality: the CAC consortium. Cardiovasc Imaging. 2020;13(5):1175\u201386.","journal-title":"Cardiovasc Imaging"},{"issue":"2","key":"1589_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003144","volume":"5","author":"U Hoffmann","year":"2016","unstructured":"Hoffmann U, Massaro JM, D\u2019Agostino RB Sr, Kathiresan S, Fox CS, O\u2019Donnell CJ. Cardiovascular event prediction and risk reclassification by coronary, aortic, and valvular calcification in the Framingham Heart Study. J Am Heart Assoc. 2016;5(2):e003144.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1589_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453\u201363.","journal-title":"Lancet Neurol"},{"key":"1589_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pcad.2026.02.004","volume":"95","author":"M Tyagi","year":"2026","unstructured":"Tyagi M, Prabhakar AP, Kalra DK. Arterial calcification as an imaging biomarker of the risk of stroke, dementia, and cognitive decline. Progr Cardiovasc Dis. 2026;95:119\u201328.","journal-title":"Progr Cardiovasc Dis"},{"issue":"11","key":"1589_CR57","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ehjci\/jez043","volume":"20","author":"M Ferencik","year":"2019","unstructured":"Ferencik M, Blankstein R, Nasir K. Unravelling the coronary artery calcium paradox: benefits of plaques of stone. Eur Heart J Cardiovasc Imaging. 2019;20(11):1305\u20136.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"1589_CR58","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.atherosclerosis.2015.05.021","volume":"241","author":"M Ferencik","year":"2015","unstructured":"Ferencik M, Chatzizisis YS. Statins and the coronary plaque calcium \u201cparadox\u201d: insights from non-invasive and invasive imaging. Atherosclerosis. 2015;241(2):783\u20135.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1589_CR59","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/eurpub\/cki053","volume":"15","author":"K Andersson","year":"2005","unstructured":"Andersson K, Melander A, Svensson C, Lind O, Nilsson JLG. Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health. 2005;15(6):621\u20136.","journal-title":"Eur J Public Health"},{"issue":"1","key":"1589_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","volume":"24","author":"CE de Keyser","year":"2014","unstructured":"de Keyser CE, Peters BJM, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, et al. The SLCO1B1 c.521T> C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genom. 2014;24(1):43\u201351.","journal-title":"Pharmacogenet Genom"},{"issue":"8","key":"1589_CR61","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"Group SC","year":"2008","unstructured":"Group SC. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"key":"1589_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/9780470756973.ch5","volume-title":"Handbook of research methods in experimental psychology","author":"RE Kirk","year":"2003","unstructured":"Kirk RE. The importance of effect magnitude. In: Handbook of research methods in experimental psychology. 2003. p. 83\u2013105."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01589-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01589-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:02:20Z","timestamp":1790258540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01589-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01589-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based on existing data from the Rotterdam Study. The present analysis was conducted under the existing Rotterdam Study ethical approvals and participant informed consent framework. No new data collection or additional procedures were performed, and no additional study-specific ethical review, approval, exemption, or waiver was obtained or required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent to participate in the Rotterdam Study and consented to the use of their medical data and pharmacy records for research purposes.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underlying this study contain information related to study participants and are therefore not publicly available. Reasonable requests for access to the data can be directed to the secretariat of the Department of Epidemiology (secretariat.epi@erasmusmc.nl). Access may be granted to qualified researchers for the purpose of replicating findings or conducting related research, subject to approval from the institutional review board and the signing of a data-sharing agreement to ensure participant confidentiality is maintained. Please visit the following website for more information:\n                      \n                      .","order":5,"name":"Ethics","label":"Data Availability and Confidentiality Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Statistical analyses were performed using RStudio. The analysis code is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MNS: Conceptualisation, data curation, formal analysis, investigation, methodology, visualisation, writing - original draft, review & editing. JAL: Methodology, review & editing. FA: Review & editing. BHS: Methodology, supervision, review & editing, validation. MK: Review & editing. DB: Supervision, review & editing, validation. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Authors Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}